4zte - Revision history

OCA at 11:01, 10 January 2024

2024-01-10T11:01:09Z

←Older revision		Revision as of 11:01, 10 January 2024
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4zte]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZTE OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4ZTE FirstGlance]. <br>		<table><tr><td colspan='2'>[[4zte]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZTE OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4ZTE FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=4RL:N-{[(2S,5S)-1-BENZYL-5-(2-{[(2S,3S)-1-(TERT-BUTYLAMINO)-3-METHYL-1-OXOPENTAN-2-YL]AMINO}-2-OXOETHYL)-3,6-DIOXOPIPERAZIN-2-YL]METHYL}-L-ALPHA-ASPARAGINE'>4RL</scene>, <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.13Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=4RL:N-{[(2S,5S)-1-BENZYL-5-(2-{[(2S,3S)-1-(TERT-BUTYLAMINO)-3-METHYL-1-OXOPENTAN-2-YL]AMINO}-2-OXOETHYL)-3,6-DIOXOPIPERAZIN-2-YL]METHYL}-L-ALPHA-ASPARAGINE'>4RL</scene>, <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4zte FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4zte OCA], [https://pdbe.org/4zte PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4zte RCSB], [https://www.ebi.ac.uk/pdbsum/4zte PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4zte ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4zte FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4zte OCA], [https://pdbe.org/4zte PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4zte RCSB], [https://www.ebi.ac.uk/pdbsum/4zte PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4zte ProSAT]</span></td></tr>
	</table>		</table>

OCA at 07:40, 18 May 2023

2023-05-18T07:40:57Z

←Older revision		Revision as of 07:40, 18 May 2023
Line 3:		Line 3:
	<StructureSection load='4zte' size='340' side='right'caption='[[4zte]], [[Resolution\|resolution]] 2.13Å' scene=''>		<StructureSection load='4zte' size='340' side='right'caption='[[4zte]], [[Resolution\|resolution]] 2.13Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4zte]] is a 2 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZTE OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4ZTE FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4zte]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZTE OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4ZTE FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4RL:N-{[(2S,5S)-1-BENZYL-5-(2-{[(2S,3S)-1-(TERT-BUTYLAMINO)-3-METHYL-1-OXOPENTAN-2-YL]AMINO}-2-OXOETHYL)-3,6-DIOXOPIPERAZIN-2-YL]METHYL}-L-ALPHA-ASPARAGINE'>4RL</scene>, <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>~~</td></tr>~~	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=4RL:N-{[(2S,5S)-1-BENZYL-5-(2-{[(2S,3S)-1-(TERT-BUTYLAMINO)-3-METHYL-1-OXOPENTAN-2-YL]AMINO}-2-OXOETHYL)-3,6-DIOXOPIPERAZIN-2-YL]METHYL}-L-ALPHA-ASPARAGINE'>4RL</scene>, <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene></td></tr>
-	~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4zt1\|4zt1]]</td></tr>~~	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4zte FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4zte OCA], [https://pdbe.org/4zte PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4zte RCSB], [https://www.ebi.ac.uk/pdbsum/4zte PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4zte ProSAT]</span></td></tr>
-	~~<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">CDH1, CDHE, UVO ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])~~</td></tr>	+
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4zte FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4zte OCA], [~~http~~://pdbe.org/4zte PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=4zte RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/4zte PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=4zte ProSAT]</span></td></tr>	+
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/CADH1_HUMAN CADH1_HUMAN]] Defects in CDH1 are the cause of hereditary diffuse gastric cancer (HDGC) [MIM:[~~http~~://omim.org/entry/137215 137215]]. An autosomal dominant cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. Note=Heterozygous germline mutations CDH1 are responsible for familial cases of diffuse gastric cancer. Somatic mutations in the has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.<ref>PMID:10319582</ref> <ref>PMID:12216071</ref> Defects in CDH1 are a cause of susceptibility to endometrial cancer (ENDMC) [MIM:[~~http~~://omim.org/entry/608089 608089]]. Defects in CDH1 are a cause of susceptibility to ovarian cancer (OC) [MIM:[~~http~~://omim.org/entry/167000 167000]]. Ovarian cancer common malignancy originating from ovarian tissue. Although many histologic types of ovarian neoplasms have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.	+	[https://www.uniprot.org/uniprot/CADH1_HUMAN CADH1_HUMAN] Defects in CDH1 are the cause of hereditary diffuse gastric cancer (HDGC) [MIM:[https://omim.org/entry/137215 137215]. An autosomal dominant cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. Note=Heterozygous germline mutations CDH1 are responsible for familial cases of diffuse gastric cancer. Somatic mutations in the has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.<ref>PMID:10319582</ref> <ref>PMID:12216071</ref> Defects in CDH1 are a cause of susceptibility to endometrial cancer (ENDMC) [MIM:[https://omim.org/entry/608089 608089]. Defects in CDH1 are a cause of susceptibility to ovarian cancer (OC) [MIM:[https://omim.org/entry/167000 167000]. Ovarian cancer common malignancy originating from ovarian tissue. Although many histologic types of ovarian neoplasms have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/CADH1_HUMAN CADH1_HUMAN]] Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. CDH1 is involved in mechanisms regulating cell-cell adhesions, mobility and proliferation of epithelial cells. Has a potent invasive suppressor role. It is a ligand for integrin alpha-E/beta-7.<ref>PMID:16417575</ref> E-Cad/CTF2 promotes non-amyloidogenic degradation of Abeta precursors. Has a strong inhibitory effect on APP C99 and C83 production.<ref>PMID:16417575</ref>	+	[https://www.uniprot.org/uniprot/CADH1_HUMAN CADH1_HUMAN] Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. CDH1 is involved in mechanisms regulating cell-cell adhesions, mobility and proliferation of epithelial cells. Has a potent invasive suppressor role. It is a ligand for integrin alpha-E/beta-7.<ref>PMID:16417575</ref> E-Cad/CTF2 promotes non-amyloidogenic degradation of Abeta precursors. Has a strong inhibitory effect on APP C99 and C83 production.<ref>PMID:16417575</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 29:		Line 27:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: ~~Lucarelli, A P]]~~	+	[[Category: Dalle Vedove A]]
-	~~[[Category: Nardone, V]]~~	+	[[Category: Lucarelli AP]]
-	~~[[Category: Parisini, E]]~~	+	[[Category: Nardone V]]
-	~~[[Category:~~ Vedove, A ~~Dalle~~]]	+	[[Category: Parisini E]]
-	[[Category: ~~Adhesion~~]]	+
-	[[Category: ~~Cadherin~~]]	+
-	[[Category: ~~Calcium-binding protein]]~~	+
-	~~[[Category: Cell adhesion]]~~	+
-	~~[[Category: Inhibitor]]~~	+
-	~~[[Category: Peptidomimetic]]~~	+
-	~~[[Category: X-dimer~~]]	+

OCA at 08:17, 26 June 2019

2019-06-26T08:17:00Z

←Older revision		Revision as of 08:17, 26 June 2019
Line 1:		Line 1:

	==Crystal structure of human E-Cadherin (residues 3-213) in complex with a peptidomimetic inhibitor==		==Crystal structure of human E-Cadherin (residues 3-213) in complex with a peptidomimetic inhibitor==
-	<StructureSection load='4zte' size='340' side='right' caption='[[4zte]], [[Resolution\|resolution]] 2.13Å' scene=''>	+	<StructureSection load='4zte' size='340' side='right'caption='[[4zte]], [[Resolution\|resolution]] 2.13Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4zte]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZTE OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ZTE FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4zte]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZTE OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ZTE FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4RL:N-{[(2S,5S)-1-BENZYL-5-(2-{[(2S,3S)-1-(TERT-BUTYLAMINO)-3-METHYL-1-OXOPENTAN-2-YL]AMINO}-2-OXOETHYL)-3,6-DIOXOPIPERAZIN-2-YL]METHYL}-L-ALPHA-ASPARAGINE'>4RL</scene>, <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4RL:N-{[(2S,5S)-1-BENZYL-5-(2-{[(2S,3S)-1-(TERT-BUTYLAMINO)-3-METHYL-1-OXOPENTAN-2-YL]AMINO}-2-OXOETHYL)-3,6-DIOXOPIPERAZIN-2-YL]METHYL}-L-ALPHA-ASPARAGINE'>4RL</scene>, <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4zt1\|4zt1]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4zt1\|4zt1]]</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4zte FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4zte OCA], [http://pdbe.org/4zte PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4zte RCSB], [http://www.ebi.ac.uk/pdbsum/4zte PDBsum]</span></td></tr>	+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">CDH1, CDHE, UVO ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4zte FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4zte OCA], [http://pdbe.org/4zte PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4zte RCSB], [http://www.ebi.ac.uk/pdbsum/4zte PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4zte ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 21:		Line 22:
	</div>		</div>
	<div class="pdbe-citations 4zte" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 4zte" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Cadherin 3D structures\|Cadherin 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Lucarelli, A P]]		[[Category: Lucarelli, A P]]
	[[Category: Nardone, V]]		[[Category: Nardone, V]]

OCA at 15:43, 1 June 2016

2016-06-01T15:43:10Z

←Older revision		Revision as of 15:43, 1 June 2016
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 4zte is ~~ON HOLD~~ ~~until Paper~~ Publication	+	==Crystal structure of human E-Cadherin (residues 3-213) in complex with a peptidomimetic inhibitor==
		+	<StructureSection load='4zte' size='340' side='right' caption='[[4zte]], [[Resolution\|resolution]] 2.13Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[4zte]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4ZTE OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ZTE FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4RL:N-{[(2S,5S)-1-BENZYL-5-(2-{[(2S,3S)-1-(TERT-BUTYLAMINO)-3-METHYL-1-OXOPENTAN-2-YL]AMINO}-2-OXOETHYL)-3,6-DIOXOPIPERAZIN-2-YL]METHYL}-L-ALPHA-ASPARAGINE'>4RL</scene>, <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene></td></tr>
		+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[4zt1\|4zt1]]</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4zte FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4zte OCA], [http://pdbe.org/4zte PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4zte RCSB], [http://www.ebi.ac.uk/pdbsum/4zte PDBsum]</span></td></tr>
		+	</table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/CADH1_HUMAN CADH1_HUMAN]] Defects in CDH1 are the cause of hereditary diffuse gastric cancer (HDGC) [MIM:[http://omim.org/entry/137215 137215]]. An autosomal dominant cancer predisposition syndrome with increased susceptibility to diffuse gastric cancer. Diffuse gastric cancer is a malignant disease characterized by poorly differentiated infiltrating lesions resulting in thickening of the stomach. Malignant tumors start in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. Note=Heterozygous germline mutations CDH1 are responsible for familial cases of diffuse gastric cancer. Somatic mutations in the has also been found in patients with sporadic diffuse gastric cancer and lobular breast cancer.<ref>PMID:10319582</ref> <ref>PMID:12216071</ref> Defects in CDH1 are a cause of susceptibility to endometrial cancer (ENDMC) [MIM:[http://omim.org/entry/608089 608089]]. Defects in CDH1 are a cause of susceptibility to ovarian cancer (OC) [MIM:[http://omim.org/entry/167000 167000]]. Ovarian cancer common malignancy originating from ovarian tissue. Although many histologic types of ovarian neoplasms have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease.
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/CADH1_HUMAN CADH1_HUMAN]] Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. CDH1 is involved in mechanisms regulating cell-cell adhesions, mobility and proliferation of epithelial cells. Has a potent invasive suppressor role. It is a ligand for integrin alpha-E/beta-7.<ref>PMID:16417575</ref> E-Cad/CTF2 promotes non-amyloidogenic degradation of Abeta precursors. Has a strong inhibitory effect on APP C99 and C83 production.<ref>PMID:16417575</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Cadherins are transmembrane cell adhesion proteins whose aberrant expression often correlates with cancer development and proliferation. We report the crystal structure of an E-cadherin extracellular fragment in complex with a peptidomimetic compound that was previously shown to partially inhibit cadherin homophilic adhesion. The structure reveals an unexpected binding mode and allows the identification of a druggable cadherin interface, thus paving the way to a future structure-guided design of cell adhesion inhibitors against cadherin-expressing solid tumors.

-	~~Authors: Nardone~~, V., Lucarelli~~, A.P.~~, Dalle Vedove, A., ~~Parisini~~, E.	+	Crystal Structure of Human E-Cadherin-EC1EC2 in Complex with a Peptidomimetic Competitive Inhibitor of Cadherin Homophilic Interaction.,Nardone V, Lucarelli AP, Dalle Vedove A, Fanelli R, Tomassetti A, Belvisi L, Civera M, Parisini E J Med Chem. 2016 May 26;59(10):5089-94. doi: 10.1021/acs.jmedchem.5b01487. Epub, 2016 May 3. PMID:27120112<ref>PMID:27120112</ref>

-	~~Description: Crystal structure~~ of ~~human E~~-~~Cadherin (residues 3~~-~~213) in complex with a peptidomimetic inhibitor~~	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	~~[[Category~~: ~~Unreleased Structures]]~~	+	</div>
-	~~[[Category: Dalle Vedove, A]]~~	+	<div class="pdbe-citations 4zte" style="background-color:#fffaf0;"></div>
-	~~[[Category: Parisini, E]]~~	+	== References ==
-	[[Category: Lucarelli, A.P]]	+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Lucarelli, A P]]
	[[Category: Nardone, V]]		[[Category: Nardone, V]]
		+	[[Category: Parisini, E]]
		+	[[Category: Vedove, A Dalle]]
		+	[[Category: Adhesion]]
		+	[[Category: Cadherin]]
		+	[[Category: Calcium-binding protein]]
		+	[[Category: Cell adhesion]]
		+	[[Category: Inhibitor]]
		+	[[Category: Peptidomimetic]]
		+	[[Category: X-dimer]]

OCA at 00:11, 1 December 2015

2015-12-01T00:11:18Z

←Older revision		Revision as of 00:11, 1 December 2015
Line 9:		Line 9:
	[[Category: Dalle Vedove, A]]		[[Category: Dalle Vedove, A]]
	[[Category: Parisini, E]]		[[Category: Parisini, E]]
-	[[Category: Nardone, V]]
	[[Category: Lucarelli, A.P]]		[[Category: Lucarelli, A.P]]
		+	[[Category: Nardone, V]]

OCA at 14:41, 27 May 2015

2015-05-27T14:41:38Z

←Older revision		Revision as of 14:41, 27 May 2015
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 4zte is ON HOLD	+	The entry 4zte is ON HOLD until Paper Publication

	Authors: Nardone, V., Lucarelli, A.P., Dalle Vedove, A., Parisini, E.		Authors: Nardone, V., Lucarelli, A.P., Dalle Vedove, A., Parisini, E.

-	Description: Crystal structure of human E-Cadherin (residues 3-213) ~~in x-dimer conformation~~ in complex with peptidomimetic inhibitor	+	Description: Crystal structure of human E-Cadherin (residues 3-213) in complex with a peptidomimetic inhibitor
	[[Category: Unreleased Structures]]		[[Category: Unreleased Structures]]
	[[Category: Dalle Vedove, A]]		[[Category: Dalle Vedove, A]]

OCA: Protected "4zte" [edit=sysop:move=sysop]

2015-05-20T11:09:23Z

Protected "4zte" [edit=sysop:move=sysop]

←Older revision

Revision as of 11:09, 20 May 2015

OCA: New page: '''Unreleased structure''' The entry 4zte is ON HOLD Authors: Nardone, V., Lucarelli, A.P., Dalle Vedove, A., Parisini, E. Description: Crystal structure of human E-Cadherin (residues ...

2015-05-20T11:09:22Z

New page: '''Unreleased structure''' The entry 4zte is ON HOLD Authors: Nardone, V., Lucarelli, A.P., Dalle Vedove, A., Parisini, E. Description: Crystal structure of human E-Cadherin (residues ...

New page

'''Unreleased structure'''

The entry 4zte is ON HOLD

Authors: Nardone, V., Lucarelli, A.P., Dalle Vedove, A., Parisini, E.

Description: Crystal structure of human E-Cadherin (residues 3-213) in x-dimer conformation in complex with peptidomimetic inhibitor
[[Category: Unreleased Structures]]
[[Category: Dalle Vedove, A]]
[[Category: Parisini, E]]
[[Category: Nardone, V]]
[[Category: Lucarelli, A.P]]